These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33747714)

  • 1. Causal inference in the face of competing events.
    Rudolph JE; Lesko CR; Naimi AI
    Curr Epidemiol Rep; 2020 Sep; 7(3):125-131. PubMed ID: 33747714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Causal inference with recurrent and competing events.
    Janvin M; Young JG; Ryalen PC; Stensrud MJ
    Lifetime Data Anal; 2024 Jan; 30(1):59-118. PubMed ID: 37173588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating causal effects in the presence of competing events using regression standardisation with the Stata command standsurv.
    Syriopoulou E; Mozumder SI; Rutherford MJ; Lambert PC
    BMC Med Res Methodol; 2022 Aug; 22(1):226. PubMed ID: 35963987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A causal framework for classical statistical estimands in failure-time settings with competing events.
    Young JG; Stensrud MJ; Tchetgen Tchetgen EJ; Hernán MA
    Stat Med; 2020 Apr; 39(8):1199-1236. PubMed ID: 31985089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothetical Estimands in Clinical Trials: A Unification of Causal Inference and Missing Data Methods.
    Olarte Parra C; Daniel RM; Bartlett JW
    Stat Biopharm Res; 2023; 15(2):421-432. PubMed ID: 37260584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
    Jin M; Liu G
    Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporating estimands into clinical trial statistical analysis plans.
    Kang M; Kendall MA; Ribaudo H; Tierney C; Zheng L; Smeaton L; Lindsey JC
    Clin Trials; 2022 Jun; 19(3):285-291. PubMed ID: 35257600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invited commentary: Estimating population impact in the presence of competing events.
    Naimi AI; Tchetgen Tchetgen EJ
    Am J Epidemiol; 2015 Apr; 181(8):571-4. PubMed ID: 25816819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of tripartite estimands using adherence causal estimators under the causal inference framework.
    Qu Y; Luo J; Ruberg SJ
    Pharm Stat; 2021 Jan; 20(1):55-67. PubMed ID: 33442928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating questions to estimands in randomized clinical trials with intercurrent events.
    Stensrud MJ; Dukes O
    Stat Med; 2022 Jul; 41(16):3211-3228. PubMed ID: 35578779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Missingness in the Setting of Competing Risks: from missing values to missing potential outcomes.
    Lau B; Lesko C
    Curr Epidemiol Rep; 2018 Jun; 5(2):153-159. PubMed ID: 30386717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the ratio of means as a causal estimand in clinical endpoint bioequivalence studies in the presence of intercurrent events.
    Lou Y; Jones MP; Sun W
    Stat Med; 2019 Nov; 38(27):5214-5235. PubMed ID: 31621943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting.
    Polito L; Liang Q; Pal N; Mpofu P; Sawas A; Humblet O; Rufibach K; Heinzmann D
    Front Pharmacol; 2024; 15():1223858. PubMed ID: 38344177
    [No Abstract]   [Full Text] [Related]  

  • 14. Connecting Instrumental Variable methods for causal inference to the Estimand Framework.
    Bowden J; Bornkamp B; Glimm E; Bretz F
    Stat Med; 2021 Nov; 40(25):5605-5627. PubMed ID: 34288021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of separable direct and indirect effects in continuous time.
    Martinussen T; Stensrud MJ
    Biometrics; 2023 Mar; 79(1):127-139. PubMed ID: 34506039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by postrandomization event occurrence.
    Magnusson BP; Schmidli H; Rouyrre N; Scharfstein DO
    Stat Med; 2019 Oct; 38(23):4761-4771. PubMed ID: 31386219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assumption Trade-Offs When Choosing Identification Strategies for Pre-Post Treatment Effect Estimation: An Illustration of a Community-Based Intervention in Madagascar.
    Weber AM; van der Laan MJ; Petersen ML
    J Causal Inference; 2015 Mar; 3(1):109-130. PubMed ID: 26097800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-world intervention graphs for defining, identifying, and communicating estimands in clinical trials.
    Ocampo A; Bather JR
    Stat Med; 2023 Sep; 42(21):3892-3902. PubMed ID: 37340887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of causal effects in clinical endpoint bioequivalence studies in the presence of intercurrent events: noncompliance and missing data.
    Lou Y; Jones MP; Sun W
    J Biopharm Stat; 2019; 29(1):151-173. PubMed ID: 29995564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.
    Fletcher C; Hefting N; Wright M; Bell J; Anzures-Cabrera J; Wright D; Lynggaard H; Schueler A
    Ther Innov Regul Sci; 2022 Jul; 56(4):637-650. PubMed ID: 35462609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.